Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB), a clinical-stage biotech company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Rand Sutherland will engage in a fireside chat on June 11, 2025, at 9:20 a.m. ET. The presentation will be accessible via live webcast in the Events section of the company's Investors page, with a replay available afterward.

WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 46^th Annual Global Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m. ET.

A live webcast of the fireside chat will be available under the “Events” tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation.

About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com

FAQ

When is Upstream Bio (UPB) presenting at the Goldman Sachs Healthcare Conference 2025?

Upstream Bio will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m. ET.

Who will represent Upstream Bio (UPB) at the Goldman Sachs Healthcare Conference?

Dr. Rand Sutherland, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the conference.

How can I watch Upstream Bio's (UPB) presentation at the Goldman Sachs Conference?

The presentation can be viewed via live webcast under the Events tab on the Investors page of Upstream Bio's website, with a replay available after the event.

What is Upstream Bio's (UPB) main focus as a company?

Upstream Bio is a clinical-stage company that develops treatments for inflammatory diseases, with a particular focus on severe respiratory disorders.